Puma Biotechnology Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
Puma Biotech (PBYI) Tops Q1 EPS by 53c, Revenues Beat
May 7, 2020 6:00 PM EDTPuma Biotech (NASDAQ: PBYI) reported Q1 EPS of ($0.20), $0.53 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $48.6 million versus the consensus estimate of $46.69 million.
We remain focused on providing a significant impact to cancer patients in need. The earlier-than-expected approval of the sNDA of NERLYNX in combination with capecitabine to treat adult patients with HER2-positive metastatic breast cancer who have... More
